Alternatively, more selective tumor antigens have been introduced in TriKE platforms such as C-type lectin domain family 12 member A (CLEC12A), which is highly expressed also on CD33− AML cells and could better contribute to myeloid leukemia targeting by NK cells [202]. This evidence concerns the gene CLEC12A and acute myeloid leukemia.